Meloxicam injection - Recro Pharma

Drug Profile

Meloxicam injection - Recro Pharma

Alternative Names: Meloxicam injection; N-1539; NanoCrystal® meloxicam

Latest Information Update: 25 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Drug Delivery Inc
  • Developer Recro Pharma
  • Class 2 ring heterocyclic compounds; Amides; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postoperative pain

Most Recent Events

  • 04 Sep 2018 Recro Pharma announces intention to resubmit NDA application for Postoperative pain in USA by end of September 2018
  • 24 Jun 2018 Biomarkers information updated
  • 24 May 2018 Recro Pharma receives complete response letter from the FDA for meloxicam intravenous injection in Post-operative pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top